Last $14.06 USD
Change Today -1.24 / -8.10%
Volume 197.7K
PETX On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 8:10 PM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

aratana therapeutics inc (PETX) Snapshot

Open
$15.25
Previous Close
$15.30
Day High
$15.25
Day Low
$13.76
52 Week High
10/16/13 - $29.32
52 Week Low
06/26/13 - $6.00
Market Cap
414.5M
Average Volume 10 Days
299.7K
EPS TTM
$-6.81
Shares Outstanding
29.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARATANA THERAPEUTICS INC (PETX)

Related News

No related news articles were found.

aratana therapeutics inc (PETX) Related Businessweek News

No Related Businessweek News Found

aratana therapeutics inc (PETX) Details

Aratana Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on the licensing, acquisition, development, and commercialization of biopharmaceutical products for cats, dogs, and other companion animals worldwide. Its product portfolio includes approximately 15 product candidates consisting of small molecule pharmaceuticals and large molecule biologics that target various opportunities in serious medical conditions in pets. The company develops AT-001, a prostaglandin E receptor 4 antagonist to treat the pain and inflammation associated with osteoarthritis in dogs, as well as for the management of pain in cats; AT-002, a ghrelin agonist for inappetence in cats and dogs; and AT-003, a bupivacaine liposome injectable suspension for the treatment of post-operative pain in cats and dogs. It also develops AT-004, a monoclonal antibody (MAB) used in the treatment of canine B-cell lymphoma; and AT-005, a MAB for the treatment of canine T-cell lymphoma in pets. The company was founded in 2010 and is headquartered in Kansas City, Kansas.

25 Employees
Last Reported Date: 03/26/14
Founded in 2010

aratana therapeutics inc (PETX) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $425.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $50.7K
Chief Development Officer
Total Annual Compensation: $286.1K
Chief Commercial Officer
Total Annual Compensation: $270.6K
Chief Scientific Officer
Total Annual Compensation: $225.0K
Compensation as of Fiscal Year 2013.

aratana therapeutics inc (PETX) Key Developments

Aratana Therapeutics, Inc. Appoints David L. Brinkley to its Board of Directors

Aratana Therapeutics, Inc. announced the appointment of former Theravance executive David L. Brinkley to its Board of Directors. Mr. Brinkley worked for Theravance, Inc., from 2000 to 2013, serving most recently as the Head of Business Development. Mr. Brinkley served previously as Senior Vice President, Commercial Development at Theravance.

Advaxis, Inc., Aratana Therapeutics, Inc. - Special Call

To discuss global licensing agreement for Advaxis' ADXS-cHER2 for the treatment of osteosarcoma in dogs and three additional cancer immunotherapy products for the treatment of three other types of cancer

Aratana Therapeutics, Inc. Announces Unaudited Consolidated Financial Results for the Fourth Quarter and Year Ended December 31, 2013; Provides Cash Flow Guidance for the Fiscal Year 2014

Aratana Therapeutics, Inc. announced unaudited consolidated financial results for the fourth quarter and year ended December 31, 2013. For the quarter, revenue was $123,000. Loss from operations was $8,135,000 against $4,254,000 a year ago. Net income attributable to common stockholders was $7,118,000 or $0.33 per basic share against net loss attributable to common stockholders of $4,747,000 or $6.50 per basic share a year ago. For the year, revenue was $123,000. Loss from operations was $19,863,000 against $11,778,000 a year ago. Net loss attributable to common stockholders was $4,287,000 or $0.39 per basic share against $13,671,000 or $34.53 per basic share a year ago. During 2014, the company plans to fully integrate the operations and development programs of Vet Therapeutics and Okapi Sciences. The company also expects to advance its development programs, further develop the canine lymphoma market with additional post-licensure marketing trials and expand its commercial capabilities in 2014. As a result, the company anticipates use of cash from operations of $35 million to $40 million in 2014 excluding the one-time payments for the recent acquisitions and cost from further business development opportunities in 2014. The company anticipates approximately $25 million to $30 million of this spending to be on clinical development and post-licensure studies.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PETX:US $14.06 USD -1.24

PETX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PETX.
View Industry Companies
 

Industry Analysis

PETX

Industry Average

Valuation PETX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2,652.1x
Price/Book 4.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3,148.9x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARATANA THERAPEUTICS INC, please visit www.aratana.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.